Multiple TRAIL-based (combo) therapies are currently explored in vitro and in clinical trials, including the cancer therapeutic potential of recombinant TRAIL, humanized TRAIL receptor-activating antibodies, TRAIL mimetic peptides, and combinatorial treatments using recombinant TRAIL and irradiation or chemotherapeutics. The gene discussed is TNFSF10; the disease is cancer.